Supplementary Protection Certificate

A Supplementary Protection Certificate (SPC) is a regulatory exclusivity right that extends the effective patent protection for pharmaceutical and plant protection products in the European Union beyond the normal 20-year patent term, to compensate for the time lost obtaining regulatory approval (marketing authorization, MA). LEGAL BASIS: EU SPC Regulation No. 469/2009 (pharmaceutical products — codified from the 1992 original); EU SPC Regulation No. 1610/96 (plant protection products); national SPC laws in EU member states and EEA countries (Switzerland has its own SPC system under Swiss patent law); WHY SPCs EXIST: the development and regulatory approval of a pharmaceutical product typically takes 10–12 years after the patent filing date; a drug company may only have 8–10 years of effective patent exclusivity remaining when the drug finally receives marketing authorization; SPCs compensate for this regulatory delay by extending protection; HOW LONG: the SPC term = date of first MA in the EU − date of patent filing − 5 years; maximum SPC term = 5 years; minimum SPC term: no SPC if the gap between filing and MA is less than 5 years; PEDIATRIC EXTENSION: an additional 6-month extension is available if the SPC holder has conducted clinical trials in pediatric populations under Regulation 1901/2006; SCOPE: the SPC covers only the specific active ingredient (or combination of ingredients) that received the MA — it does not extend the entire parent patent's claims.

The four conditions for SPC eligibility under EU Regulation 469/2009 (Article 3) are: (1) THE PRODUCT MUST BE PROTECTED BY A BASIC PATENT IN FORCE: the active ingredient (or combination) must be protected by a patent claim; the basic patent need not specifically name the active ingredient — it can be a claim to a class of compounds that covers the product; the patent must still be in force at the time of SPC application; (2) A VALID MA (MARKETING AUTHORIZATION) MUST HAVE BEEN GRANTED FOR THE PRODUCT: the first MA in the EU (either centralized via EMA or national) must have been granted; the MA must be the first authorization to place the product on the market as a medicinal product; (3) THE PRODUCT MUST NOT ALREADY HAVE BEEN THE SUBJECT OF AN SPC: only one SPC per product per country; if a prior SPC was granted in the same country for the same active ingredient, a second SPC cannot be obtained (but a different basic patent can support a NEW SPC for a combination that includes the ingredient); (4) THE MA MUST BE THE FIRST AUTHORIZATION FOR PLACEMENT OF THE PRODUCT ON THE EU MARKET: this requires identifying the FIRST ever MA in the EU — earlier national MAs in EU member states count; COMPLEX SCENARIOS: combination products (multiple active ingredients) may qualify under Medeva and Eli Lilly CJEU rulings — each ingredient must be specified in the patent claims (not merely functional claims); EXCLUSION — REGULATORY EXCLUSIVITY OVERLAP: if a product has orphan drug exclusivity under EU Regulation 141/2000, the SPC runs concurrently with the orphan exclusivity; the SPC provides protection even after the 10-year orphan exclusivity expires.

The SPC term calculation is straightforward once the key dates are identified: FORMULA: SPC duration = (Date of first MA in EU) − (Date of patent filing) − 5 years; MAXIMUM TERM: 5 years (SPC expires 15 years after first MA); MINIMUM TERM: if the gap between patent filing and first MA is less than 5 years, no SPC is available (the formula yields zero or negative); APPLICATION DEADLINE: the SPC application must be filed within 6 months of the MA date, OR within 6 months of the patent grant date — whichever is later; EXAMPLE: patent filing date: January 1, 2005; first EU MA date: January 1, 2020; gap = 15 years; SPC term = 15 − 5 = 10 years; maximum cap = 5 years; actual SPC = 5 years; SPC expiry = January 1, 2025 (5 years after MA); WITHOUT SPC: patent expiry = January 1, 2025 (20 years from filing); WITH SPC: effective exclusivity extends to January 1, 2025 (no benefit because patent term and SPC both expire on the same date); PEDIATRIC EXTENSION CALCULATION: +6 months added to the SPC expiry (or to the basic patent expiry if no SPC was granted); the pediatric extension requires a completed pediatric investigation plan (PIP) and a pediatric-labeled MA; COUNTRY-BY-COUNTRY: SPCs are national rights — an SPC must be applied for in each EU member state separately; the filing date, duration, and proceedings differ slightly by country; centralized procedure (EMA) MAs are the first EU MA for most new drugs.

SPC applications are filed at the national patent office of each EU member state where protection is sought: APPLICATION PROCEDURE: (1) file SPC application at the national patent office within 6 months of the later of: (a) first MA date in the EU; (b) patent grant date; (2) pay the national filing fee; (3) submit: the basic patent number; the MA number and date; the MA holder's name; any prior SPC applications (must disclose); (4) national patent office examines for compliance with the 4 Article 3 conditions; (5) grant or refusal decision; CJEU REFERENCES: because SPC conditions are defined by EU regulations, national courts frequently refer interpretation questions to the Court of Justice of the EU (CJEU); key CJEU rulings on SPC eligibility have shaped practice significantly (Massachusetts General Hospital — C-553/13; Medeva — C-322/10; Teva v. Gilead — C-121/17); REVOCATION: SPCs can be revoked if the basic patent is found invalid, if the product was not authorized, or if the first MA was earlier than stated; TRANSFER: SPCs can be assigned, licensed, or inherited with the basic patent; LAPSE: SPCs lapse if the annual renewal fees are not paid (most EU countries require annual fees after the basic patent expires); SPC WAIVERS AND MANUFACTURING EXEMPTION (2019 REFORM): Regulation 2019/933 introduced an EU manufacturing exemption allowing generics and biosimilar manufacturers to manufacture in an EU member state during the SPC term, for: (a) export to non-SPC countries; (b) stockpiling for entry on Day 1 of SPC expiry in EU markets.

The EU currently has no SPC system for medical devices — SPCs apply only to pharmaceutical products and plant protection products under their respective regulations. However, combination drug-device products (a drug incorporated into or combined with a device) may qualify for an SPC based on the medicinal product component: DRUG-DEVICE COMBINATIONS: if a combination product obtains a marketing authorization as a 'medicinal product' (drug-led combination), the drug active ingredient may be the basis for an SPC; the device component cannot independently support an SPC; DIAGNOSTIC PRODUCTS: in vitro diagnostics (IVDs) are not 'medicinal products' and do not qualify for EU SPCs; BIOLOGICS AND BIOSIMILARS: biologics (antibodies, fusion proteins, recombinant proteins) can qualify for SPCs if they obtain an MA as a medicinal product; the active ingredient for biologic SPCs is typically the specific protein or antibody molecule; biosimilar manufacturers must wait for SPC expiry (or the 2019 manufacturing exemption); PROPOSED EU SPC REFORM: the European Commission proposed a unified EU SPC system (replacing the current 27 national SPC systems) as part of the broader EU pharmaceutical and IP legislation reform (Unitary Patent/UPC context); if enacted, a unitary SPC would cover all EU member states; as of 2026, the reform is still under legislative consideration; US EQUIVALENT: in the United States, the Hatch-Waxman Act provides patent term restoration (PTR) under 35 U.S.C. § 156 as the functional equivalent of the EU SPC — restoring up to 5 years of patent term lost during FDA regulatory review; the USPTO administers PTR applications.